JP2014528486A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528486A5
JP2014528486A5 JP2014535977A JP2014535977A JP2014528486A5 JP 2014528486 A5 JP2014528486 A5 JP 2014528486A5 JP 2014535977 A JP2014535977 A JP 2014535977A JP 2014535977 A JP2014535977 A JP 2014535977A JP 2014528486 A5 JP2014528486 A5 JP 2014528486A5
Authority
JP
Japan
Prior art keywords
dione
benzyl
thiazolidine
methyl
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/060262 external-priority patent/WO2013056232A2/en
Publication of JP2014528486A publication Critical patent/JP2014528486A/ja
Publication of JP2014528486A5 publication Critical patent/JP2014528486A5/ja
Pending legal-status Critical Current

Links

JP2014535977A 2011-10-13 2012-10-15 Ｒｘｒアゴニスト化合物および方法 Pending JP2014528486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546777P 2011-10-13 2011-10-13
US61/546,777 2011-10-13
PCT/US2012/060262 WO2013056232A2 (en) 2011-10-13 2012-10-15 Rxr agonists compounds and methods

Publications (2)

Publication Number Publication Date
JP2014528486A JP2014528486A (ja) 2014-10-27
JP2014528486A5 true JP2014528486A5 (OSRAM) 2015-12-03

Family

ID=48082779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535977A Pending JP2014528486A (ja) 2011-10-13 2012-10-15 Ｒｘｒアゴニスト化合物および方法

Country Status (4)

Country Link
US (1) US20140235676A1 (OSRAM)
EP (1) EP2766018A4 (OSRAM)
JP (1) JP2014528486A (OSRAM)
WO (1) WO2013056232A2 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510114A (ja) 2005-09-30 2009-03-12 ビテ ファーマシューティカルズ， インコーポレイテッド 特定のｒｘｒアゴニストによる癌治療
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
BR112014029161A2 (pt) * 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
WO2015187850A2 (en) * 2014-06-03 2015-12-10 Duke University Compounds and methods for treatment of ocular disorders
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN104490867A (zh) * 2014-12-03 2015-04-08 沈阳药科大学 苯甲酸衍生物在制备抗血管新生药物中的用途
WO2016153949A1 (en) * 2015-03-20 2016-09-29 Deuterx, Llc 5-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using same
WO2016191312A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
PL3368080T3 (pl) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
SG11201807250PA (en) * 2016-03-10 2018-09-27 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
CN115227826A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
WO2018175707A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
KR102841468B1 (ko) * 2018-03-01 2025-08-04 디제이 테라퓨틱스 엘엘씨 벡사로텐 유도체 및 암 치료에서 이의 용도
JP7295128B2 (ja) 2018-03-02 2023-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 小分子核内受容体モジュレータのアミドプロドラッグ
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
EP3887401A2 (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
JP2024544223A (ja) 2021-12-07 2024-11-28 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用
JP2024543621A (ja) 2021-12-07 2024-11-21 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306284A (pt) * 1992-04-22 1998-01-13 Ligand Pharm Inc Compostos tendo seletividade pra receptores de retinóides x
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
US20030008273A1 (en) * 2001-06-11 2003-01-09 Thomas Perlmann Methods for increasing the survival of neuronal cells
US20040092589A1 (en) * 2002-06-21 2004-05-13 Liisa Neumann Use of retinoic acid for treatment of autism
US20050003998A1 (en) * 2002-08-15 2005-01-06 Goran Bertilsson Therapeutic use of selective LXR modulators
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US20080027031A1 (en) * 2006-03-08 2008-01-31 Kinemed, Inc. Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
EP2451455A4 (en) * 2009-07-10 2013-01-16 Univ Case Western Reserve RXR AGONIST COMPOUNDS AND METHODS
US9132170B2 (en) * 2011-07-29 2015-09-15 Case Western Reserve University Compositions and methods for treating cognitive deficits

Similar Documents

Publication Publication Date Title
JP2018016657A (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
JP2009545613A5 (OSRAM)
RU2018138707A (ru) Замещенные гетероарилом пиридины и способы применения
JP2019517455A5 (OSRAM)
HRP20161116T1 (hr) NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3
JP2009534386A5 (OSRAM)
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
JP2010519181A5 (OSRAM)
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JP2015509510A5 (OSRAM)
JP2010525056A5 (OSRAM)
ME02606B (me) Jedinjenja 1,3 - oksazolidina ili 1,3- oksazinana kao antagonisti oreksinskog receptora
JP2016534124A5 (OSRAM)
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
HRP20140588T1 (hr) Spojevi kondenziranog prstena i njihova uporaba
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
JP2013507397A5 (OSRAM)
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
JP2019501134A5 (OSRAM)
WO2013070463A3 (en) Treatment of blood lipid abnormalities and other conditions
SI3801515T1 (sl) 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni
BR112022021951A2 (pt) Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial
JP2014532688A5 (OSRAM)